Le Bouëdec G, Kauffmann P, Pingeon J M, de Latour M, Lemesle P, Dauplat J
Service de Chirurgie, Centre Jean Perrin, Clermont-Ferrand.
Rev Fr Gynecol Obstet. 1991 May;86(5):407-10.
The authors report a case of endometriosis (adenomyosis + endometrioma) which occurred in a female patient aged 69 years, who had undergone the menopause 15 years previously and who had been taking Tamoxifen for 7 years as an adjuvant treatment for cancer of the breast. Tamoxifen, a non-steroidal anti-estrogen derived from diethylstilbestrol, has a variable antagonist/agonist so that estrogenic stimulation of the female genital tract may occur, particularly of the endometrial mucosa. The reactivation of the endometriosic foci which had become quiescent under the impact of the natural menopause, which, by iatrogenic analogy is included in the series of paradoxical uterine effects of tamoxifen.
作者报告了一例子宫内膜异位症（子宫腺肌病+子宫内膜瘤），发生在一名69岁的女性患者身上，该患者15年前已绝经，并且作为乳腺癌辅助治疗服用他莫昔芬7年。他莫昔芬是一种从己烯雌酚衍生而来的非甾体抗雌激素药物，具有可变的拮抗剂/激动剂作用，因此可能会对女性生殖道产生雌激素刺激，尤其是子宫内膜黏膜。在自然绝经影响下已静止的子宫内膜异位病灶重新激活，从医源性角度类推，这属于他莫昔芬引起的一系列子宫反常效应。
